Navigation Links
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
Date:9/23/2011

ignificant improvement in skin lesions including facial angiofibromas was observed, which can be a key concern for people living with TSC."  

Everolimus targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(8). Tuberous sclerosis complex is caused by defects in the TSC1 and/or TSC2 genes(9). When these genes are defective, mTOR activity is increased, which can cause uncontrolled tumor cell growth and proliferation, blood vessel growth and altered cellular metabolism(2,9). By inhibiting mTOR activity in this signaling pathway, everolimus may reduce cell proliferation and blood vessel growth related to angiomyolipoma associated with TSC(2,8,9).

"The positive findings seen in this trial coupled with the known efficacy of everolimus in patients with SEGA point to the important role of mTOR inhibition with everolimus in treating these manifestations of TSC," said Herve Hoppenot, President, Novartis Oncology. "The outcomes support our further research efforts evaluating everolimus as a treatment option across the various conditions associated with TSC."

Affecting approximately 25,000 to 40,000 people in the US and one to two million people worldwide, TSC is associated with a variety of resulting disorders including skin lesions, seizures, swelling in the brain (hydrocephalus) and developmental delays(3,9).

About EXIST-2 EXIST-2 is a prospective, double-blind, randomized, parallel group, placebo-controlled, international, multicenter Phase III study of everolimus versus placebo for the treatment of patients with angiomyolipoma associated with TSC(1,10). Trial patients (median age=31, range 18-61) were randomized 2:1 to receive either everolimus (n=79) or placebo (n=39) at a daily starting dose of 10 mg. By the cut-off of June 30, 2011, the median treatment duration in the double-blind period was 38.1 weeks (range 2-105 weeks) in the everolimus arm and 3
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Novartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. Novartis Drug Gleevec® Shows Significant Overall Survival Benefit for Patients With GIST After Three Years of Adjuvant Treatment vs. One Year
4. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
5. Novartis Data Shows ACZ885 for Severe Gouty Arthritis Provided Better Pain Relief and Reduced Risk of New Attacks by Up to 68% vs. Steroid
6. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
7. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
8. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
9. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
10. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
11. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Rock Creek Pharmaceuticals, Inc. (NASDAQ: ... announced that the Food and Drug Administration ("FDA"), has ... on RCP,s Investigational New Drug ("IND") application before granting ... the US. Dr. Chris Chapman , ... comments on our IND. When we receive the agency,s ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... the addition of the "Immunoprotein Diagnostic Testing ... at the highest CAGR of 6% and is ... report to their offering. ... for immunoprotein diagnostic testing has been segmented according ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... GREEN BAY, Wis., Sept. 16 Top researchers at ... Center in Dallas are exploring the clinical applications of ... potency, and bioavailability. Previous studies have ... than other forms of curcumin, and had a retention ...
... Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic... -- REGENSBURG, Germany, September ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; ...
Cached Medicine Technology:BCM-95 Demonstrates Superior Anti-Inflammatory Effects 2Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 2Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 3Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 4Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 5Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 6Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 7Transcatheter Technologies Successfully Performs in Vivo Implantation of the Trinity Transapical Aortic Valve System 8
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... 2014 Recently, MyDressCity.com, one of the ... occasion outfits, has released its new range of ... products are available at discounted prices. Worldwide clients can ... , In the company’s online shop, there are plenty ... are made with great materials. MyDressCity.com’s hot items are ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Celebrity fitness ... has formed a promotional partnership with Aqua Health Labs ... Omega-3 EPA supplement . The collaboration was recently ... celebrity fitness trainer , actor, model, and a ... trainer for A-List celebrities, he has prepared stars including ...
Breaking Medicine News(10 mins):Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2
... , NAPA, Calif., Aug. 19 Dey ... today issued an advisory regarding two lots of its Albuterol Sulfate ... that was stolen in McKinney, Texas. , , ... brand name "DEY" and contains thirty 3ml single-dose vials. The lot ...
... , , , ... released the following statement after President Obama said that it,s ... the health care reform plans. , , ... "Tonight, President Obama deliberately misled the American people by ...
... , , , ... one of four companies to have been awarded a contract to ... The contract becomes effective October 1, 2009. , , ... work with the State of Arizona and offer our innovative health ...
... Aug. 19 (HealthDay News) -- People with lung cancer who ... a drug called Tarceva, which is believed to work well ... who take the drug, new research has found. , According ... 20 issue of the New England Journal of Medicine ...
... NEW YORK, Aug. 19 One of the few bright spots of ... and HBA Global Expo ( www.hb a e ... activists to deliver a Keynote Presentations on Tuesday, September 15, 2009 at ... New York. Horst M. Rechelbacher, founder of Intelligent Nutrients and ...
... a novel robot-assisted endoscopic technique, a team of surgeons ... has successfully treated 200 consecutive patients with thyroid cancer. ... cosmetic benefits that the traditional open operation does not ... Journal of the American College of Surgeons . ...
Cached Medicine News:Health News:Dey Issues Advisory 2Health News:President Obama Misleads on Abortion Funding in Health Care Reform 2Health News:CIGNA Awarded State of Arizona Health Care Contract 2Health News:Gene Mutation Improves Response to Lung Cancer Drug 2Health News:Gene Mutation Improves Response to Lung Cancer Drug 3Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 2Health News:Horst M. Rechelbacher To Deliver HBA Global Expo Keynote Address 3Health News:New robot-assisted surgical method found successful for treatment of thyroid cancer 2
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
Medicine Products: